<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta name="Generator" content="SAS Software Version 9.4, see www.sas.com">
<meta http-equiv="Content-type" content="text/html; charset=utf-8">
<title>SAS Output</title>
<style type="text/css">
<!--
.accessiblecaption
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.aftercaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.batch
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  padding: 7px;
}
.beforecaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.body
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  margin-left: 8px;
  margin-right: 8px;
}
.bodydate
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  text-align: right;
  vertical-align: top;
  width: 100%;
}
.bycontentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.byline
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.bylinecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.caption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.cell
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.container
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.contentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contentprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contents
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.contentsdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.contenttitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.continued
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  width: 100%;
}
.data
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.dataemphasis
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataemphasisfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataempty
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datafixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datastrong
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.datastrongfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.date
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.document
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.extendedpage
{
  background-color: #FFFFFF;
  border: 1pt solid #000000;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
  text-align: center;
}
.fatalbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.folderaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footer
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.frame
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.graph
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.header
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.headersandfooters
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.index
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.indexprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.indextitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.linecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.note
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notebanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.output
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.pageno
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  text-align: right;
  vertical-align: top;
}
.pages
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.pagesdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.pagesitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.pagesproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagesprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagestitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.paragraph
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.parskip
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.prepage
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitlefixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooter
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooteremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooteremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooterempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowfooterstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheader
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderemphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderemphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowheaderstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.systemfooter
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemtitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systitleandfootercontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.table
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.top_stacked_value
{
  padding-bottom: 1px;
  border: 0;
}
.middle_stacked_value
{
  padding-top: 1px;
  padding-bottom: 1px;
  border: 0;
}
.bottom_stacked_value
{
  padding-top: 1px;
  border: 0;
}
.titleandnotecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.titlesandfooters
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.usertext
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warnbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.l {text-align: left }
.c {text-align: center }
.r {text-align: right }
.d {text-align: right }
.j {text-align: justify }
.t {vertical-align: top }
.m {vertical-align: middle }
.b {vertical-align: bottom }
TD, TH {vertical-align: top }
.stacked_cell{padding: 0 }
-->
</style>
<script language="javascript" type="text/javascript">
<!-- 
function startup(){

}
function shutdown(){

}

//-->
</script>

</head>
<body onload="startup()" onunload="shutdown()" class="body">

<script language="javascript" type="text/javascript">
<!-- 
var _info = navigator.userAgent
var _ie = (_info.indexOf("MSIE") > 0
          && _info.indexOf("Win") > 0
          && _info.indexOf("Windows 3.1") < 0);
var _ie64 = _info.indexOf("x64") > 0

//-->
</script>

<div class="branch">
<a name="IDX"></a>
<table class="systitleandfootercontainer" width="100%" cellspacing="1" cellpadding="1" rules="none" frame="void" border="0" summary="Page Layout">
<tr>
<td class="c systemtitle">Acylcarnitine data set 2</td>
</tr>
</table><br>
<div>
<div align="center">
<table class="table" cellspacing="1" cellpadding="7" rules="none" frame="box" summary="Procedure Print: Data Set REF2.ACYLCARNITINE_SORTED_2">
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="l header" scope="col">Title</th>
<th class="l header" scope="col">Research_Gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="l data">A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes</td>
<td class="l data">(A) Treatment with dapagliflozin in fasting situation =&gt; increases AA&#39;s and decreases lipid species. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Bioinformatic procedures =&gt; metabolic pathways =&gt; protective of renal function for SGLT2i dapagliflozin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXx (C) Overlap in gene expression between (1) Metabolites targeted by dapagliflozin. (2) Intra-renal transcripts assoc. DKD =&gt; upregulation of pathway of BCAA corresponding BCAA&#39;s not changed. (3) Urea + urea cycle metabolites increased. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased levels of short chain acyl-carnitines reduced levels of myristoylcarnitine (long chain acyl-carnitines). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) FAO incomplete surplus acyl-groups exported from mitochondria as acylcarnitines. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Reduced levels of acylcarnitines =&gt; larger degree of complete FAO. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Long chain acylcarnitines =&gt; fasting =&gt; increased short chain acylcarnitines. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) 3-Hydroxy FA reduces by dapagliflozin + high levels 3-OH FA&#39;s =&gt; markers of FAO disorders. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Improved FAO + increased fasting response, surplus 2- and 4-chain carbons. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Obese non-diabetic mice + canagliflozin =&gt; activation of catabolic pathways =&gt; FAO + mTOR inhibition + activation of AMPK. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Dapagliflozin =&gt; increased TCA cycle activity =&gt; increased expression of several TCA enzymes =&gt; eGFR =&gt; +ve effect on renal mitochondrial function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) DKD =&gt; increased levels of metabolites + intermediates of TCA cycle + endoplasmic reticulum stress. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Cause of reduced TCA-cycle intermediates not clear explained by; (1) Improved mitochondrial efficacy. (2) Larger degree of complete FAO + increased gluconeogenesis (liver + kidney) =&gt; to compensate for urinary glucose loss. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Kynurenine redn =&gt; increased activity =&gt; picolinic acid increased + NAD+ further support improved mitochondrial function after dapagliflozin treatment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Long term protective effects of SGLT2i&#39;s on kidney =&gt; amelioration of mitochondrial function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) SGLT2i =&gt; improves endothelial function + prevents accelerated renal function decline mechn =&gt; increased glycaemic control, metabolic control, osmotic duiresis + natriuresis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) Dapagliflozin targeted pathways assoc. with DKD, molecular processes related to (1) energy metabolism (2) mitochondrial function (3) endothelial function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Dapagliflozin slows progression of DKD. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Future research =&gt; refer to point (p). XXXXXXXXXXXXXXXXXXXXXXXXXXXX     XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) The exact mechanism of how SGLT2 inhibition improves endothelial function is not fully understood but may involve improved glycaemic and metabolic control, osmotic diuresis, and changes in sodium homeostasis as a result of increased natriuresis.</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="l data">Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With TypeÂ 2 Diabetes and Kidney Disease</td>
<td class="l data">(A) Profiling of acylcarnitines =&gt; incomplete FAO + increased catabolism of AA&#39;s =&gt; T2D + kidney disease. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Redn in plasma phosphatidylcholine levels + elevation of long-chain sphingomyelin + ceramide levels =&gt; remodelling of sphingolipids in T2D with DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C)Impaired renal filtration function + albuminuria levels =&gt; different metabolite signatures. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Targeted metabolomics =&gt; excellent survey of energy-yield pathways + fuel substrate selection. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Incomplete FAO =&gt; increased B-oxidn-derived even-number acylcarnitines. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Acceleration in catabolism of AA&#39;s esp. AAA&#39;s =&gt; DKD. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Increased levels of AA-derived acylcarnitines  + redn plasma levels of tyrosine + tryptophan =&gt; DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Excess intracellular + circulating acylcarnitines =&gt; excerbate metabolic disturbance =&gt; cytotoxicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Accumulation of FAO + AA-derived metabolic intermediates in plasma =&gt; progression of DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Elevation of cluster of dicarboxyl + hydroxyl-carnitines in plasma =&gt; DKD XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Increased formation of dicarboxyl + hydroxyl dicarboxylic acids u-FAO + u-1 FAO =&gt; corresponding acylcarnitines =&gt; acyl-Co-A accumulation in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) u-Oxidn =&gt; rescue pathway =&gt; mitochondrial FAO is impaired. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Endoplasmic retuculum stress =&gt; increased short chain diacid levels =&gt; accumulation =&gt; short + long-chain dicarboxylcarnitines =&gt; indicate mitochondrial stress and / or endoplasmic reticulum stress =&gt; activation of alternative FAO pathways =&gt; DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Accumulation of acetyl-Co-A-derived C2 (acetyl-carnitine) =&gt; mismatch =&gt; energy substrate flux or utilization in DKD. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Unable to ascertain whether imbalance =&gt; accelerated flux or redn in downstream utilization or BOTH. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Mitochrondrial function is impaired in DKD, redn electron transport chain (ETC) activaties + overall redn mitochondrial content + PGC-1a expression =&gt; DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Similar defects =&gt; diabetic islet, heart + skeletal muscle. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Impaired mitochondrial function partially explained by substrate flux / oxidn imbalance in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) IR + other related metabolic disturbance in DKD =&gt; impair mitochondria + restrict its ability to select glucose =&gt; preferred substrate for oxidn (metabolic inflexibility). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Fuel supply + oxidn may not necessarily be reduced in presence of mitochondrial dysfunction. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Frank mitochondrial dysfunction (myopathies with impaired ETC activity) =&gt; increase fuel flux + oxidn =&gt; compensate for impaired ATP synthesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Impaired mitochondrial function + energy substrate oversupply in T2D =&gt; intra-mitochonrial metabolic intermediates accumulation + extracellular overflow =&gt; circulation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Future in-vivo tracing study =&gt; isotope-labelled substrate =&gt; insights into substrate flux, selection + oxidization in DKD. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Long-chain sphingomyelin + ceramides increased in DKD sphingomyelin-ceramide pathway =&gt; renal complications. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Pathological mechns =&gt; mitochondrial impairment + increased generation of ROS, activation of apoptotic pathway, increased inflammatory tone + endoplasmic reticulum stress + contribute to overprodn short-chain diacids + long-chain dicarboxylacylcarnitine in DKD. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Redn phosphatidyl-choline + increment in sphingomyelin levels =&gt; sphingolipid remodelling in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX phosphatidyl-choline =&gt; choline phosphotransferase =&gt; sphingomyelin. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Renal filtration function + albuminuria levels =&gt; eGFR + ACR (albumin / creatinine ratio) =&gt; independent of predictors of CKD progression + genetic studies no overlap loci of eGFR + ACR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Assoc sphingomyelin + albuminuria =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sphingomyelin =&gt; inhibition =&gt; ceramide (redn albumin excretion, protection of kidney function) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Sphingomyelin =&gt; ceramide metabolism =&gt; independently assoc. with albuminuria BUT not renal filtration in T2D. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Previous studies polymorphism of ceramide synthase 2 (CerS2) =&gt; changes in albuminuria BUT NOT eGFR in T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E1) Increased albumuria redn eGFR complimentary + overlapping =&gt; kidney damage. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Inverse assoc acylcarnitine levels + eGFR =&gt; non diabetic popns. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Acylcarnitine sub-species differed in non-DKD + DKD, short-chain diacids + AA-derived acylcarnitines =&gt; strong / independent association with eGFR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Altered energy substrate selection XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Imbalance of substrate flux + utilization. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Remodelling of sphingolipids in T2D + DKD XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Distinct metabolite signatures eGFR + albuminuria =&gt; different pathophysiological process underlying eGFR + albuminuria DKD in T2D.</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="l data">Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study</td>
<td class="l data">(A) Applying a MS-based acylcarnitine profiling platform =&gt; panel of acylcarnitines =&gt; esp. assoc. future risk of T2D =&gt; substantially improved predictive ability for incident T2D beyond conventional risk, inc BMI + fasting glucose. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Previous studies =&gt; obese + diabetic animal models =&gt; links of acylcarnitines =&gt; mild FAO dysregulation + mitochondrial stress =&gt; worsened IR + glucose deterioration. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Treating myotube + acylcarnitine =&gt; Akt phosphorylation + glucose uptake in response to insulin stimulation. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Redn of mitochondrial FA import or acylcarnitine synthesis =&gt; alleviate lipid-induced IR =&gt; lipid-induced  =&gt; mitochonrial stress =&gt; predates the emergence of glucose deterioration + diabetes. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Previous studies =&gt; acylcarnitine profiles, associated with insulin sensitivity, plus sig. different acylcarnitine profiles =&gt; normal glucose tolerance (NGT), prediabetic (impared glucose tolerance (IGT) +/- impaired fasting glucose (IFG)) + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Several prospective studies =&gt; medium and / or long-chain acylcarnitines =&gt; predicted cardiovascular events or mortality in &gt; 85 years or selected patients undergoing cardiac catheterization or dialysis. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) European studies targeted BIOCRATES metabolomics platform =&gt; no sig. assoc acylcarnitines + incident T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Differences in =&gt; study design methodology + statistical analyses + ethnic differences + lifestyle =&gt; explain discrepancy between our study + others. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Current study =&gt; selected acylcarnitines added to predictive models =&gt; substantially improved predictive ability =&gt; T2D beyond conventional risk factors e.g. BMI + fasting glucose (AUCs: 0.89 vs 0.73). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Simple alternative approach =&gt; assess mitochondrial FAO dysregulation in vivo =&gt; specific acylcarnitine patterns =&gt; promising early biomarkers =&gt; T2D =&gt; long chain acylcarnitines =&gt; increased incident T2D. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Long chain FA&#39;s =&gt; oxidized predominately inside mitochondrion. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) LCFA&#39;s =&gt; transported across the mitochondrion inner membrane as long-chain acylcarnitine. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Initial metabolites of B-oxidn =&gt; accumulation of long chain acylcarnitine =&gt; reflect severe conditions of FAO dysregulation + mitochondrial overload + impaired tricarboxylic acid (TCA) cycle. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Obese + T2D subjects =&gt; increased non-esterified + long-chain acylcarnitines vs non-case subjects. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Underlying mechn unclear =&gt; in-vitro studies =&gt; treatment with long chain acylcarnitines =&gt; induced IR + oxidative stress in human myotubes + regulated calcium efflux in cardiac tissue + Human Ether-a-go-go-Related Gene (hERG) channels in renal cells. Potential functional roles =&gt; LCFA derivative =&gt; beyond biomarkers of mitochondrial dysfunction. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) The associations of medium-chain acylcarnitines + T2D remain uncertain, explanations could include, different precursors or metabolic compartments that are involved =&gt; generation of medium-chain acylcarnitines which could be later B-oxidn metabolites of LCFA or directly esterified derivatives from MCFA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) MCFA&#39;s =&gt; pro-inflammatory agents in some studies in-vitro, BUT antimicrobial, anti-inflammatory agents in other studies in-vivo + in-vitro. MCFA&#39;s in metabolic disorders =&gt; remains to be elucidated. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Increased circulating 3-dehydroxycarnitine + 3-dehydrocarnitine =&gt; precursors of L-carnitine prodns =&gt; assoc lower risk incident T2D. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Previously, carnitine, improves insulin-stimulated glucose utilization + T2D-related metabolic disorders =&gt; humans + rodents. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Mechn =&gt; unclear =&gt; admin of 3-dehydroxycarnitine =&gt; mouse model lacking L-carnitine transporter =&gt; improved FA metabolism =&gt; potential benefits =&gt; carnitine precursors =&gt; maintaining energy homeostasis. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Findings =&gt; dicarboxylic acid acylcarnitines with odd chains or even chains =&gt; different impacts on the development of T2D. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Malonylcarnitine (C3DC) =&gt; indicator =&gt; reflect malonyl-CoA levels. Malonyl-Co-A =&gt; key regulators =&gt; mammalian energy homeostasis =&gt; inhibiting mitochondrial CPT1 + FAO. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) IR-patients with obesity + T2D =&gt; high muscle malonyl-Co-A concns. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Remains unclear whether malonyl-CoA accumulation =&gt; indicated by accumulated C3DC =&gt; serves as a feedback signal =&gt; suppress B-oxidn + mitochondrial stress =&gt; blocking CPT1 activity =&gt; to counteract lipid-induced IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) +ve C3DC-diabetes assoc. in our study =&gt; role of malonyl-CoA =&gt; diabetes pathogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Unlike odd-chain dicarboxylic acids, even chain dicarboxylic acids =&gt; derived from v-oxidn of FA&#39;s thereafter =&gt; B-oxidn. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Intervention studies =&gt; sebacic acid (C10DC FA) + dodecanedioic acid (C12DC FA) =&gt; favourable impacts on glycaemic control + energy utilization =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Inverse assoc. of C10DC + C12DC acylcarnitines =&gt; incident T2D =&gt; supported potential benefits of sebacic acid + dodecanoic acid in T2D. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Elastic net model =&gt; successful =&gt; predictive accuracy + sparsity =&gt; high-dimensional data sets =&gt; used in variable selection + model selection.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Acylcarnitines =&gt; sig. improved predicting power of T2D vs conventional risk factors =&gt; potential utility =&gt; novel early predictors of T2D risk assessment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) These findings need to be replicated in other populations, and underlying biological mechanisms should be elucidated in future studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="l data">Biomarkers of rapid chronic kidney disease progression in type 2 diabetes</td>
<td class="l data">(A) T2D + CKD3 =&gt; large set of candidate and global discovery biomarkers =&gt; at least 62 =&gt; evidence of association with rapid renal function decline. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Many biomarkers =&gt; high correlations with each other  + clinical covariates =&gt; a much sparser set of 14 biomarkers =&gt; contained the most predictive information beyond clinical covariates. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (C) These biomarkers =&gt;  incremental prediction that was sufficient in magnitude =&gt; provide risk stratification into clinical trials. Some biomarkers are already known to be associated with eGFR (B2-microglobulin + cystatin-C). Others are unknown biomarkers associated with eGFR (SDMA (symmetric dimethylarginine) / ADMA (Asymmetric dimethylarginine) ratio, FGF-21 + uracil). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D) The best biomarker predictive panel =&gt; restricted clinical covariates + 35 biomarkers, BUT only modestly better than the best sparse model =&gt; 14 biomarkers =&gt; expense + logistics favoured the 14 biomarker (sparse) model vs best biomarker predictor model (clinical covariates + 35 biomarkers). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX    (E) Used clinical creatinine measurements to calculate eGFR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Focused the study on more novel biomarker associations. Strongest biomarker associations =&gt; released during proteolytic breakdown of nuclear proteins =&gt; studied as biomarkers for CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (G) SDMA =&gt; excreted via the kidney =&gt; strongly associated with renal function, BUT =&gt; protein methyl-transferase (PRMT5) =&gt; synthesizes SDMA =&gt; ALSO regulates interleukin-2-gene expression =&gt; higher SDMA levels =&gt; may reflect inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (H) No asssociation of SDMA =&gt; C-reactive protein inflammatory biomarker, BUT +ve correlation (r=0.39) with interleukin-2 receptor a levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Study finding =&gt; SDMA accumulates when kidney filtration falls =&gt; good biomarker of filtration. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) In contrast to SDMA =&gt; ADMA =&gt; weakly inversely correlated =&gt; eGFR, BUT strongly correlated =&gt; arginine. The SDMA / ADMA ratio =&gt; biomarker of these complex interactions. SDMA / ADMA =&gt; had higher predictive power (AUROC) vs SDMA or ADMA separately. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (K) KIM-1 =&gt; protein expressed on apical membrane =&gt; proximal tubule cells =&gt; ectodomain =&gt; shed into the lumen =&gt; serves as a urinary biomarker of kidney injury =&gt; mixed results =&gt; prognostic biomarker =&gt; diabetic kidney disease. KIM-1 expression increased =&gt; glomerulus of diabetic animal models + elevated plasma levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Shed KIM-1 =&gt; serves as a blood biomarker in kidney injury in humans =&gt; plasma KIM-1 levels higher in patients with acute kidney injury (AKI) vs healthy controls or post-cardiac surgery patients without AKI. A study serum KIM-1 level at baseline =&gt; T1D =&gt; strongly predicted rate of eGFR loss + risk of ESRD =&gt; 5 - 15 years of FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (M) Associations =&gt; rapid progression of two fibroblast growth factors =&gt; FGF-21 + FGF-23. FGF-21 =&gt; 181 AA polypeptide =&gt; secreted in liver + adipose tissue =&gt; role in lipid + energy metabolism. Previous studies cross-sectional association with eGFR. Median serum FGF-21 levels =&gt; &gt; 7-15-fold higher in dialysis patients vs controls, BUT fell after short term angiotensin blockade. Crossectional associations =&gt; FGF-21 levels elevated =&gt; albuminuria when eGFR &gt;60ml/min. FGF-21 =&gt; independently associated =&gt; urinary albumin in T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Kidney =&gt; relatively low levels of FGF-21 =&gt; FGF-21 activity =&gt; depends on tissue specific expression =&gt; cofactor Klotho B =&gt; predominantly in liver + adipose tissue vs kidney. Association of FGF-21 + renal disease progression =&gt; simple accumulation in renal disease. However =&gt; may reflect =&gt; antifibrotic response =&gt; FGF-21 =&gt; prevented expression of profibrotic cytokines =&gt; transforming growth factor-B1 in the kidney. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) FGF-23 =&gt; 32-kD bone-derived hormone =&gt; several known endocrine functions in the kidney + promotion of urinary phosphate excretion + inhibition =&gt; hydroxylation =&gt; 25-hydroxyvitamin D. Elevated FGF-23 =&gt; independent risk factor for ESRD =&gt; in patients with perserved kidney function + mortality across a spectrum of CKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Atheroscelerosis Risk in Communities study (ARIC) =&gt; higher serum level FGF-23  =&gt; increased risk =&gt; incident ESRD, independent of baseline level of kidney function + other risk factors. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) C 16-acylcarnitine =&gt; strongest predictors =&gt; rapid progression. KORA study =&gt; acylcarnitine =&gt; ratio of serine to glutarylcarnitine =&gt; associated with eGFR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) However, further studies of the generalizability of findings are warranted. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Validation in external cohorts is needed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) It is not possible to conclude that biomarkers that are associated with progression at this stage will also be predictive of progression in individuals with CKD1 or CKD2 and studies are needed to examine biomarkers in such individuals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Identified novel associations of biomarkers that warrant further investigation for relevance to pathogenesis of kidney disease in type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="l data">Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver</td>
<td class="l data">(A) Body fat + ectopic lipid compartments =&gt; liver fat content correlates most strongly =&gt; insulin sensitivity. Some subjects =&gt; accumulate large amounts of fat within the liver, YET remain insulin sensitive =&gt; unexplained finding. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Increase data supporting existence of such a phenotype + investigation of mechanisms determining this phenotype =&gt; advance our knowledge  =&gt; specifically =&gt; signalling + detoxification pathways =&gt; regulation of insulin sensitivity in NAFL. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (C) Plasma metabolomic approach =&gt; metabolite pattern =&gt; BCAA&#39;s, leucine + isoleucine, ornithine the acylcarnitines C 3:0-, C 16:0- + C 18:0- carnitine + lyso-PC C 16:0 separates =&gt; insulin sensitive / insulin-resistant NAFL groups =&gt; high discriminative power. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D) This metabolomic pattern =&gt; separated NAFL groups after lifestyle intervention + after liver fat content + insulin sensitivity had changed =&gt; similar relationships for liver fat + insulin sensitivity =&gt; still apparent between groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E) Metabolomic pattern used to separate NAFL groups =&gt; BCAA&#39;s =&gt; important for the regulation of glucose metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) 1st degree relatives of T2D not only glucose + FA metabolism + leucine metabolism =&gt; resistance to insulin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Our study =&gt; correlations =&gt; leucine + isoleucine =&gt; insulin sensitivity =&gt; baseline =&gt; 40 subjects with NAFL, in contrast to what we had expected these relationships +ve. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Smaller group 17 subjects without NAFL =&gt; relationships =&gt; -ve, + strong interaction effect of circulating BCAA&#39;s with NAFL NOT with BMI to determine insulin sensitivity small sample size =&gt; caused this observation. Further studies =&gt; role of BCAA&#39;s =&gt; regulation of insulin sensitivity + NAFL. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Although we have no explanation for this novel observation, and cannot rule out that the relatively small sample size may have brought about this finding, it may be of importance for further studies on the role of BCAAs in the regulation of insulin sensitivity, particularly in the aspect of NAFL. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Although we have no explanation for this novel observation, and cannot rule out that the relatively small sample size may have brought about this finding, it may be of importance for further studies on the role of BCAAs in the regulation of insulin sensitivity, particularly in the aspect of NAFL. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Whether these effects and putatively beneficial effects of lyso-PC C16:0 on glucose uptake in other tissues translate into a positive effect on whole-body glucose uptake needs to be investigated in future studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) In support of this hypothesis,we found lyso-PC C16:0 to be negatively associated with insulin resistance in subjects with high, but not low, liver tissue lipid content. Certainly, because of the very small sample size of this group, we cannot draw definite conclusions from this observation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) In conclusion, in the future, a metabolomic fingerprint, most robust in the class of lyso-PCs, may be able to differentiate insulin-sensitive from insulin-resistant subjects with NAFL. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Furthermore, as low lyso-PC levels appear to specifically be a marker of NAFL-associated insulin resistance, these findings may highlight novel and interesting pathways for the studies on the pathogenesis of insulin resistance in NAFL. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="l data">Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach</td>
<td class="l data">(A) Targeted metabolomic approach at population level, =&gt;  increased concentrations of hexose; phenylalanine; and diacyl-phosphatidyl-cholines =&gt; C32:1, C36:1, C38:3, + C40:5 and reduced concentrations of glycine; sphingomyelin C16:1; acyl-alkylphosphatidylcholines C34:3, C40:6, C42:5, C44:4, and C44:5; + lysophosphatidylcholine C18:2 =&gt; independently predictive of T2D in EPIC-Potsdam. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (B) Results =&gt; agree with data =&gt; cross-sectional studies =&gt; T2D patients =&gt; increased concentrations =&gt; sugar metabolites, acylcarnitines + BCAA + reduced concns of glycine. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (C) Another study replicated BCAA&#39;s + AAA&#39;s =&gt; predicted T2D =&gt; prospective Framingham Offspring cohort + Malmo Diet + Cancer study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D) Higher concns =&gt; phenylalanine, isoleucine, tyrosine + valine =&gt; increased risk T2D + glycine reduced risk T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E) Our Study =&gt; BCAA&#39;s + AAA&#39;s =&gt; linked to each other =&gt; only phenylalanine independently associated with T2D risk after adjusting for other metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (F) BCAA&#39;s =&gt; substrates =&gt; glucose-alanine cycle in skeletal muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (G) Alanine =&gt; alanine aminotransferase =&gt; pyruvate =&gt; hepatic gluconeogenesis =&gt; glucose. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (H) Conversely =&gt; glycine =&gt; gluconeogenic AA&#39;s =&gt; reduced glycine levels =&gt; reflect increased gluconeogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Glycine depletion =&gt; glutathione consumption driven by oxidative stress or by abundance of incompletely oxidized fuels =&gt; excreted as urinary acylglycine conjugates. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (J) Increased BCAA&#39;s in subjects with IR =&gt; reduced activities of BCAA catabolic enzymes =&gt; liver + adipose. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) AA&#39;s may directly cause muscular IR by disrupting insulin signalling. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) IR conditions =&gt; body aims to compensate for reduced glucose uptake in peripheral tissues =&gt; increasing pancreatic insulin secretion. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) At a stage of overt IR =&gt; this system is exhausted =&gt; caused by B cell dysfunction =&gt; insulin secretion decreases. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Phenylalanine =&gt; +vely correlated  =&gt; insulin secretion + may be involved in pathways to compensate for early stages of IR through stimulation of insulin secretion. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (O) CONCLUSIONS =&gt; Identified metabolites part of different pathways involved in early genesis of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) Novel candidates  =&gt; useful in clinical practice =&gt; identify high-risk individuals earlier =&gt; delay / prevent disease onset. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Serum metabolites =&gt; predicted risk of T2D =&gt; similar manner to combn of risk factors =&gt; measurement =&gt;useful approach to predict T2D risk for individuals in the future. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (R) Prospective investigation =&gt; metabolomic data of independent study popns =&gt; identified =&gt; sugar metabolites, AA&#39;s + choline-containing-phospholipids =&gt; independently associated  =&gt; risk of T2D. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) The metabolites could also serve as markers for specific metabolic pathways that are deranged and, thereby, allow the implementation of individualized preventive and therapeutic strategies. However, future investigations are warranted to calculate in detail the individual risks and to better understand the metabolic effects of these biomarkers and their biological mechanisms. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Beyond the classic pathways, these candidates point toward a novel role of phospholipid and lipoprotein metabolism in T2D pathophysiology. Future studies should further elucidate the biological mechanisms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="l data">alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population</td>
<td class="l data">(A) Non-targeted biochemical screening approach =&gt; non-diabetic subjects =&gt; wide spectrum of insulin sensitivity =&gt; a-hydroxybutyrate (a-HB) =&gt; biomarker =&gt; segregating =&gt; clamp-derived IR with NGT. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) a-HB segregated with dysglycaemia (IFG + IGT) independently of + in addition to IR. Associations =&gt; independent of sex, age + BMI. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) a-HB =&gt; diagnostic tool =&gt; identify IR and / or IGT earlier vs currently used clincial tests. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) a-HB =&gt; organic acid derived from a-ketobutyrate (a-KB). a-KB produced by amino acid catabolism (threonine + methionine) + glutathione anabolism (cysteine formation pathway) + metabolized =&gt; propionyl-Co-A + carbon dioxide. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) a-HB =&gt; by product =&gt; during the during the formation of a a-KB via a reaction catalyzed by lactate dehydrogenase (LDH) or a-hydroxybutyrate dehydrogenase (a-HBDH) =&gt; isoform present in the heart. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Accumulation of a-HB is postulated to occur in vivo when either: XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) Formation of a-HB exceeds the rate of its catabolism which leads to substrate accumulation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) Product inhibition of the dehydrogenase that catalyzes the conversion of a-KB to propionyl-CoA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Methionine =&gt; (S-adenosylmethionine) SAM =&gt; methyltransferase =&gt; S-adenosylhomocysteine =&gt; homocysteine =&gt; cystathionine =&gt; homoserine =&gt; a-ketobutyrate =&gt; propionylCoA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Threonine =&gt; a-ketobutyrate =&gt; propionylCoA. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) a-KB is also produced cystathionine to cysteine under conditions of increased oxidative stress =&gt; higher flux of cysteine into prodn of glutathione =&gt; primary anti-oxidant in cells =&gt; shift in homocysteine prodn from transmethylation of methionine =&gt; transsulfuration of homocysteine =&gt; cystathionine. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) a-HB =&gt; assoc excess glutathione demand + disrupted mitochondrial energy metabolism =&gt; derives from hepatic glutathione stress =&gt; supporting increased a-HB assoc. increased oxidative stress in IR state. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) a-HB =&gt; increased by 2 mechns: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) Increase of hepatic glutathione stress =&gt; increased demand for glutathione prodn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) Elevation NADH/NAD+ ratio =&gt; increased lipid oxidn. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) 1st mechn =&gt; increased a-HB formation by supplying more a-KB from increased cysteine anabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Cystathionine &lt;=&gt; increased cysteine =&gt; increased Glutamate =&gt; GSH (Glutathione). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Consistent with this interpretation =&gt; statistically significant increased both a-KB + cysteine with increased IR =&gt; similar trend with a-HB. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) 2nd mechn =&gt; increased lipid oxidn =&gt; metabolic feature of IR =&gt; indexed =&gt; insulin-inhibited FFA concn. +ve assoc. =&gt; steady state FFA + plasma a-HB concns + increased NADH/NAD+ ratio favours =&gt; redn of a-KB to a-HB. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Changes in other important IR-associated metabolites =&gt; metabolic pathways =&gt; formation of a-HB + a-KB =&gt; e.g. redn glycine levels + serine upstream of a-KB formn =&gt; consistent increase gluconeogenesis =&gt; observed in IR db- / db- mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Redox imbalance =&gt; may contribute increased a-HB in context of IR =&gt; consistent =&gt; branched-chain (BC) alpha-keto acids eg. 3-methyl-2-oxobutyrate increase in IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Increases BC-a-keto acid =&gt; due to effect of redox imbalance =&gt; directionality of the dehydrogenases =&gt; reduce / oxidize these keto acids. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) a-HB =&gt; increase in T2D subjects + animal models of T2D + severe lactic acidosis + ketoacidosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Normal subjects / T2D  patients =&gt; restoration of the NADH /NAD+ redox balance by glutathione infusion therapy =&gt; increased insulin sensitivity + B-cell function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Recent study =&gt; metabolic signature =&gt; accumulation of BCAA&#39;s, the glutamine / glutamate couple, several acylcarnitines + same AAA&#39;s (phenylalanine + tyrosine) =&gt; related to IR (HOMA index) =&gt; marking the metabolic consequences of excessive fat + protein intake with impairment of insulin signalling + mitochondrial overload. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Non-targeted metabolomics approach =&gt; present study =&gt; lipid molecules, BCAA&#39;s + acylcarnitines =&gt; top 30 metabolite that RF analysis associated with M-value. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Current data =&gt; narrow down the complex interactions of AA + lipid metabolism =&gt; highlight importance of a single marker, a-HB =&gt; reflects oxidative burden in context of IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Unmet need =&gt; practical clinical test =&gt; accurately measures IR =&gt; a-HB =&gt; significant biomarker =&gt; separating IR + IS subjects =&gt; using fasting plasma sample =&gt; development of diagnostic test. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) a-HB + biochemical + clinical parameters =&gt; useful =&gt; clinical indicator of subclinical abnormalities of glucose metabolism. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
</tbody>
</table>
</div>
</div>
<br>
</div>
</body>
</html>
